FDA Inspection 1263921 — Ingenus Pharmaceuticals GmbH

Ingenus Pharmaceuticals GmbH — FEI 3005403232

The FDA completed an inspection of Ingenus Pharmaceuticals GmbH on Oct 3, 2024 in Barbengo. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Oct 3, 2024
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Barbengo (Switzerland)

Additional details

Mutual Recognition Agreement (MRA)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.